Clinical Research professional Program

Welcome to KRC Inc. On-line training!

          

Session 1 INTRODUCTION: CAREERS IN CLINICAL RESEARCH, Drug Approval Process in the USA and Canada
Session 2  Pharmaceutical Industry Overview
Session 3 Start Clinical Research Process: Drug Discovery, Drug research.
Session 4

Pre-clinical Research Pre-Clinical Studies of Drug / Product Candidates

Session 5 Investigational New Drug Application (I.N.D.) in USA  and New Drug Submission (NDS) in Canada
Session 6 Phases of Clinical Trials
Session 7

Good Clinical Practice & International Conference on Harmonization
Session 8 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
Session 9 CLINICAL TRIAL INVESTIGATOR
Session 10 MONITORING OF CLINICAL INVESTIGATIONS
Session 11 Study Initiation
Session 12 Study Monitoring
Session 13 Recruitment, Retention and Compliance
Session 14 Study Closeout
Session 15 COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS
Session 16 Choice of Control Group In Clinical Trials
Session 17 CLINICAL TRIAL SPONSOR
Session 18

CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT (S)
Session 19 CLINICAL TRIAL  INVESTIGATOR'S BROCHURE
Session 20 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Session 21 ADVERSE REACTIONS IN CLINICAL TRIALS
Session 22 INFORMED CONSENT
Session 23 SAFETY IN CLINICAL TRIALS
Session 24

Medical Dictionary for Regulatory Activities (MedDRA)
Session 25 Inspection Strategy for Clinical Trials
Session 26 Avoiding Fraud in Clinical Trials
Session 27 Financial Disclosure by Clinical Investigators
Session 28 Safety Pharmacology Studies for Human Pharmaceuticals
Session 29 recruitment of volunteers for clinical trials
Session 30

Drug Advertising
SESSION 31 GENERAL PRINCIPLES OF PHARMACOLOGY
SESSION 32 PRINCIPLES OF PHARMACODYNAMICS, TRANSDUCTION AND NEUROTRANSMISSION
SESSION 33 KINETIC PRINCIPLES OF DRUG ADMINISTRATION (Pharmacokinetic)
SESSION 34 DRUG INTERACTIONS AND METABOLISM
SESSION 35 DRUGS ACTING ON THE SYMPATHETIC NERVOUS SYSTEM (ADRENERGIC DRUGS)
SESSION 36 ANTIBIOTICS
SESSION 37 DRUGS AFFECTING THE COAGULATION SYSTEM
SESSION 38 DRUGS USED IN TREATMENT OF ALLERGIES
SESSION 39 TREATMENT OF CENTRAL NERVOUS SYSTEM DEGENERATIVE DISORDERS
SESSION 40 DRUGS FOR THE TREATMENT OF VIRAL DISEASES
SESSION 41 CHEMOTHERAPY OF NEOPLASTIC DISEASES
SESSION 42 DRUGS ACTING ON THE PARASYMPATHETIC NERVOUS SYSTEM (CHOLINERGIC DRUGS)
SESSION 43 DRUGS USED IN DERMATOLOGY
SESSION 44 CARDIAC GLYCOSIDES, ANTIARRHYTHICS AND DRUGS, USED IN ISCHEMIC HEART DISEASE
SESSION 45 HORMONES, VITAMINS, AND MINERALS.
SESSION 46 HYPOTENSIVE DRUGS AND LIPIDS-LOWERING DRUGS
SESSION 47 OPIOID DRUGS
SESSION 48 NSAIDs - NONSTEROIDAL ANTIINFLAMMATORY DRUGS
SESSION 49  ONCOLOGICAL CLINICAL TRIALS           
SESSION 50 HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT  (HIPAA)
PROJECT I Efficacy of the lowering effect of PROLIPOSTAT® on Blood concentrations of low-density lipoprotein cholesterol (LDL-C) in patients with normal and elevated blood concentrations of LDL-C
PROJECT II Phase II Study the Efficacy of the healing effect of recombinant human epidermal growth factor (rhEGF) on diabetic foot ulcers
PROJECT III Phase I Study the safety and Dose determination of Immuno - Stimulatory Therapy Agent for Bladder cancer, melanoma and colon cancer.
PROJECT IV Survey: Proper Use and Cost Reduction strategies for prescription and non-prescription drugs 
Final EXAM Exam for Clinical Research Associates
Resume Help Resume Help Session

Follow this link to Review KRC Inc. SOP-s and forms

Click HERE for Abbreviations and Acronyms

Click HERE for Glossary/ Definitions

CRA Definitions

Recommended bibliography

Your  CRA Training and Practice Proposed Schedule

 

 

Contact Us

Privacy Policy - Terms of Use

 

Copyright Kriger Research Center Inc. 2003

Hit Counter